{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:18:24Z","timestamp":1793229504170,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>This study aimed to describe oral anticoagulant (OAC) use among patients with venous thromboembolism (VTE).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>This study included Medicare fee-for-service beneficiaries (data from 1\/1\/2014-12\/31\/2019) newly diagnosed with VTE. Factors associated with being untreated with OACs in the first month from VTE (vs. OAC-treated), with receiving direct-acting OACs ([DOACs] vs. warfarin), and with extended OAC treatment (&gt;3 months) were assessed using multivariable logistic regressions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 169,928 patients with VTE (50.3% OAC-untreated) were included. Among the 49.7% OAC-treated patients, 74.0% used DOACs and 62.5% had extended OAC treatment. Factors associated with being untreated with OACs in the first month from VTE (odds ratio; 95% confidence interval) included Hispanic ethnicity (vs. White;1.35; 1.29\u20131.42), having part D low-income subsidy (1.14; 1.07, 1.20), and comorbidities such as cardiovascular diseases. Among the OAC-treated cohort, patients with index VTE diagnosis in the emergency room (vs. outpatient) setting had higher odds of receiving DOAC vs. warfarin; patients with pulmonary embolism diagnosis (vs. deep vein thrombosis) had higher odds of extended OAC treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study of Medicare patients newly diagnosed with VTE, half of the patients were not treated with OAC in the first month from initial diagnosis. Factors such as Hispanic ethnicity, having low-income subsidy, and comorbidity burden were found to be associated with being untreated with OAC. Among OAC-treated patients, the majority were treated with DOAC vs. warfarin. Interestingly, more than a third of OAC-treated patients were not treated beyond 3 months, which warrants further investigation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0321106","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:42:25Z","timestamp":1744911745000},"page":"e0321106","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral anticoagulant use among Medicare patients newly diagnosed with venous thromboembolism (VTE): Factors associated with treatment status"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-3751","authenticated-orcid":true,"given":"James C.","family":"Coons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-648X","authenticated-orcid":true,"given":"Aolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stellhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-394X","authenticated-orcid":true,"given":"Abigail","family":"Zion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"Deeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7669-075X","authenticated-orcid":true,"given":"Dionne M.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"8","key":"pone.0321106.ref001","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: A report from the American Heart Association","volume":"147","author":"C Tsao","year":"2023","journal-title":"Circulation"},{"issue":"4 Suppl","key":"pone.0321106.ref002","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"MG Beckman","year":"2010","journal-title":"Am J Prev Med"},{"issue":"5","key":"pone.0321106.ref003","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archinte.159.5.445","article-title":"Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study","volume":"159","author":"J Heit","year":"1999","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"pone.0321106.ref004","doi-asserted-by":"crossref","first-page":"832.e13-21","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort","volume":"126","author":"V Tagalakis","year":"2013","journal-title":"Am J Med"},{"key":"pone.0321106.ref005","volume-title":"Pulmonary embolism is common and can be deadly, but few know the signs","author":"M Merschel","year":"2021"},{"issue":"10063","key":"pone.0321106.ref006","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"M Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"pone.0321106.ref007","article-title":"Venous thromboembolism: Initiation of anticoagulation.","volume-title":"UpToDate","author":"GYH Lip","year":"2023"},{"issue":"19","key":"pone.0321106.ref008","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"TL Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"pone.0321106.ref009","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"SM Stevens","year":"2021","journal-title":"Chest"},{"issue":"3","key":"pone.0321106.ref010","doi-asserted-by":"crossref","first-page":"e234059","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"G Iyer","year":"2023","journal-title":"JAMA Network Open"},{"key":"pone.0321106.ref011","article-title":"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects.","volume-title":"UpToDate","author":"LLK. Leung","year":"2023"},{"issue":"14","key":"pone.0321106.ref012","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"MA de Winter","year":"2023","journal-title":"Eur Heart J"},{"issue":"24","key":"pone.0321106.ref013","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1161\/CIR.0000000000000769","article-title":"Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association","volume":"141","author":"PK Henke","year":"2020","journal-title":"Circulation"},{"key":"pone.0321106.ref014","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"F Khan","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"pone.0321106.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"M Nicholson","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0321106.ref016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J","volume":"12","author":"T van der Hulle","year":"2014","journal-title":"Thromb Haemost"},{"issue":"10","key":"pone.0321106.ref017","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/phar.1991","article-title":"Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics","volume":"37","author":"I Mohammad","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"12","key":"pone.0321106.ref018","doi-asserted-by":"crossref","first-page":"e2137288","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries","volume":"4","author":"KM Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"pone.0321106.ref019","first-page":"290","article-title":"Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature","volume":"115","author":"DJ Daly","year":"2023","journal-title":"J Natl Med Assoc"},{"issue":"12","key":"pone.0321106.ref020","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamacardio.2022.3704","article-title":"Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry","volume":"7","author":"UR Essien","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"23","key":"pone.0321106.ref021","doi-asserted-by":"crossref","first-page":"e023428","DOI":"10.1161\/JAHA.121.023428","article-title":"Disparities in Anticoagulation Use by Race and Ethnicity in Long-Term Care Residents With Atrial Fibrillation","volume":"10","author":"A Kapoor","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"pone.0321106.ref022","doi-asserted-by":"crossref","first-page":"e005600","DOI":"10.1161\/CIRCOUTCOMES.119.005600","article-title":"Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States","volume":"12","author":"AS Nathan","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"pone.0321106.ref023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","article-title":"Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship","volume":"11","author":"NH Holford","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"pone.0321106.ref024","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s40620-022-01413-x","article-title":"A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"K Parker","year":"2022","journal-title":"J Nephrol"},{"issue":"11","key":"pone.0321106.ref025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2022.1920","article-title":"Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism","volume":"327","author":"A Pawar","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"pone.0321106.ref026","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/cts.13433","article-title":"Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism","volume":"16","author":"H Park","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"4","key":"pone.0321106.ref027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2015.02.001","article-title":"Duration of anticoagulation after venous thromboembolism in real world clinical practice","volume":"135","author":"W Ageno","year":"2015","journal-title":"Thromb Res"},{"key":"pone.0321106.ref028","doi-asserted-by":"crossref","first-page":"991376","DOI":"10.3389\/fmed.2022.991376","article-title":"Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboemb\u00f3lica registry","volume":"9","author":"A Lorenzo","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:42:33Z","timestamp":1744911753000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321106"}},"subtitle":[],"editor":[{"given":"Tomohiko","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0321106","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}